LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_001083116.3:c.626A>C
PRF1
· NP_001076585.1:p.(Gln209Pro)
· NM_001083116.3
GRCh37: chr10:72358851 T>G
·
GRCh38: chr10:70599095 T>G
Gene:
PRF1
Transcript:
NM_001083116.3
Final call
VUS
PS4 strong
PM2 supporting
Variant details
Gene
PRF1
Transcript
NM_001083116.3
Protein
NP_001076585.1:p.(Gln209Pro)
gnomAD AF
1.9207010682815426e-05 (v4.1)
ClinVar
Uncertain significance
OncoKB
Classification rationale
Interpretation summary
Generated evidence synthesis
1
PS4 strong: one affected-patient carrier versus 31 matched controls produced OR 10.06 with a 95% CI excluding 1.
2
PM2 supporting: gnomAD v4.1 filtering grpmax FAF was 1.883e-05 with zero homozygotes.
Final determination:
Under generic ACMG/AMP 2015 fallback rules, one strong pathogenic criterion plus one supporting criterion does not meet a listed pathogenic or likely pathogenic combination, and no benign rule is satisfied; therefore the call is VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PS1 | Not assessed | Not assessed: no validated pathogenic comparator with the same amino-acid change, independent of the nucleotide change, was available for PRF1 p.Gln209Pro. |
clinvar
|
| PS2 | Not assessed | Not assessed: no documented proband disease with confirmed maternity and paternity, de novo status, and absence of family history. |
|
| PS3 | Not assessed | Not assessed: no variant-specific validated functional assay or assay result for PRF1 c.626A>C (p.Gln209Pro) was available. |
|
| PS4 | Met | Met: one carrier among 1892 affected patients versus 31 among 589971 matched controls gives OR 10.06 (95% CI 1.37–73.76), exceeding the OR >5.0 threshold with CI excluding 1. |
PMID:32542393
gnomad_v4
|
| PM1 | Not assessed | Not assessed: residue 209 lacks supplied evidence of a critical functional domain or mutational hotspot without benign variation. |
hotspots
|
| PM2 | Met | Met at supporting strength: gnomAD v4.1 grpmax FAF is 1.883e-05, below the <=0.0001 PM2 threshold, with zero homozygotes. |
gnomad_v4
gnomad_v2
|
| PM3 | Not assessed | Not assessed: a pathogenic partner is mentioned, but no affected-proband observation or parent/offspring testing establishes trans phase. |
clinvar
|
| PM4 | N/A | Not applicable: PM4 requires a protein-length change, and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PM5 | Not assessed | Not assessed: no different pathogenic missense change at PRF1 residue 209 was supplied as a comparator for p.Gln209Pro. |
pm5_candidates
clinvar
|
| PM6 | Not assessed | Not assessed: no parental testing or other documented evidence supports assuming that this variant arose de novo. |
|
| PP1 | Not assessed | Not assessed: no variant-specific affected relatives, co-segregation results, or meioses are documented for this family. |
|
| PP2 | Not assessed | Not assessed: the supplied evidence does not establish both low benign missense variation and a common missense disease mechanism for PRF1. |
|
| PP3 | Not met | Not met: the missense REVEL score is 0.42, below the generic supporting PP3 threshold of 0.644. |
revel
|
| PP4 | Not met | Not met: HLH is genetically heterogeneous across 15 genes in the source cohort, so the phenotype is not highly specific for a single genetic etiology. |
PMID:32542393
|
| PP5 | Not met | Not met: ClinVar has one single-laboratory Pathogenic assertion but zero expert-panel submissions and conflicting overall classifications. |
clinvar
|
| BA1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 1.883e-05, far below the >=0.05 BA1 stand-alone threshold. |
gnomad_v4
gnomad_v2
clinvar
|
| BS1 | Not met | Not met: gnomAD v4.1 filtering grpmax FAF is 1.883e-05, below the generic >=0.01 BS1 frequency threshold. |
gnomad_v4
gnomad_v2
|
| BS2 | Not assessed | Not assessed: gnomAD shows zero homozygotes, but no identified healthy adult observation with documented age, health, and relevant zygosity is available. |
gnomad_v4
gnomad_v2
|
| BS3 | Not assessed | Not assessed: no variant-specific validated assay demonstrated normal PRF1 protein function or splicing for p.Gln209Pro. |
|
| BS4 | Not assessed | Not assessed: no informative affected relatives are documented whose genotypes could demonstrate lack of segregation with disease. |
|
| BP1 | Not assessed | Not assessed: loss-of-function disease mechanism is supported, but predominance of truncating PRF1 disease variants is not established. |
|
| BP2 | Not assessed | Not assessed: a pathogenic partner is mentioned, but cis/trans phase and the fully penetrant dominant context required for BP2 are undocumented. |
clinvar
|
| BP3 | N/A | Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| BP4 | Not met | Not met: the missense REVEL score is 0.42, above the generic supporting BP4 threshold of 0.29 and therefore gray-zone. |
revel
|
| BP5 | Not met | Not met: the reported second variant is also in PRF1, and no alternate molecular basis for the patient's disease is documented. |
PMID:32542393
|
| BP6 | Not met | Not met: ClinVar provides no exact-variant expert-panel benign or likely benign classification and reports zero expert-panel submissions. |
clinvar
|
| BP7 | N/A | Not applicable: BP7 requires a synonymous variant, and this is a missense variant. |
generic_acmg_combination_rules
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.